斯钙素2在肿瘤中的研究进展

国际肿瘤学杂志››2018,Vol. 45››Issue (10): 615-618.doi:10.3760/cma.j.issn.1673-422X.2018.10.008

余计赏,吴帆

510220 暨南大学医学院附属广州红十字会医院普通外科

收稿日期:2018-08-01出版日期:2018-10-08发布日期:2018-12-21
通讯作者:吴帆 E-mail:wufan7911@163.com
基金资助:

国家自然科学基金（81000989）；广东省医学科研基金（A2017517）；广州市卫生计生科技项目（20171A011250）

Advances of stanniocalcin 2 in tumors

Yu Jishang, Wu Fan

Department of General Surgery, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou 510220, China

Received:2018-08-01Online:2018-10-08Published:2018-12-21
Contact:Wu Fan E-mail:wufan7911@163.com
Supported by:

National Natural Science Foundation of China (81000989); Research Foundation for Medical Science and Technology of Guangdong Province of China (A2017517); Science and Technology Program for Medicine and Health of Guangzhou City (20171A011250)

摘要/Abstract

摘要：斯钙素2是一种分泌型糖蛋白激素，在多种人类恶性肿瘤中表达升高。斯钙素2通过多条信号传导通路参与肿瘤增殖、凋亡、侵袭转移、缺氧耐受和化疗耐药等诸多生物学事件的调控，提示其可能是肿瘤分子调控网络中的一处重要节点。深入阐述斯钙素2在肿瘤中的作用机制，有望为肿瘤的临床诊疗提供一个新的分子标志物和治疗靶点。

关键词:肿瘤,细胞增殖,细胞凋亡,肿瘤转移,斯钙素2

Abstract:Stanniocalcin 2, a secreted glycoprotein hormone, has been found to be highly expressed in a variety of human malignancies. Through several signal transdution pathways, stanniocalcin 2 plays important roles in the regulation of many biological events of tumor such as proliferation, apoptosis, invasion and metastasis, hypoxia tolerating and drug resistance, indicating stanniocalcin 2 may be a pivotal node in the molecular regulation network of tumor. Stanniocalcin 2 is expected to become a novel biomarker and therapeutic target for diagnosis and treatment of tumor if the funtional mechanisms of stanniocalcin 2 could be further elaborated.

Key words:Neosplasms,Cell proliferation,Apoptosis,Neoplasm metastasis,Stanniocalcin 2

余计赏,吴帆. 斯钙素2在肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2018, 45(10): 615-618.

Yu Jishang, Wu Fan. Advances of stanniocalcin 2 in tumors[J]. Journal of International Oncology, 2018, 45(10): 615-618.

参考文献

［1］ Chu SJ, Zhang J, Zhang R, et al. Evolution and functions of stanniocalcins in cancer［J］. Int J Immunopathol Pharmacol, 2015, 28(1): 14-20. DOI: 10.1177/0394632015572745. ［2］ Na SS, Aldonza MB, Sung HJ, et al. Stanniocalcin2 (STC2): a potential lung cancer biomarker promotes lung cancer metastasis and progression［J］. Biochim Biophys Acta, 2015, 1854(6): 668676. DOI: 10.1016/j.bbapap.2014.11.002. ［3］ Zhang ZH, Wu YG, Qin CK, et al. Stanniocalcin 2 expression predicts poor prognosis of hepatocellular carcinoma［J］. Oncol Lett, 2014, 8(5): 2160-2164. DOI: 10.3892/ol.2014.2520. ［4］ Chen B, Zeng X, He Y, et al. STC2 promotes the epithelialmesenchymal transition of colorectal cancer cells through AKTERK signaling pathways［J］. Oncotarget, 2016, 7(44): 71400-71416. DOI: 10.18632/oncotarget.12147. ［5］ Wu J, Lai M, Shao C, et al. STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of highgrade serous ovarian cancer［J］. Oncol Rep, 2015, 34(3): 1494-1502. DOI: 10.3892/or.2015.4120. ［6］ Semaan A, Goltz D, Branchi V, et al. Clinicopathological significance of stanniocalcin2 expression in adenocarcinomas of biliary tract［J］. Int J Clin Exp Pathol , 2016, 9(8): 8351-8358. ［7］ Shen XJ, Gu K, Shi JP, et al. Increased expression of stanniocalcin 2 is associated with tumor progression after radiotherapy in patients with cervical carcinoma［J］. Int J Clin Exp Pathol, 2014, 7(12): 8770-8776. ［8］ Hashemzadeh S, Arabzadeh AA, Estiar MA, et al. Clinical utility of measuring expression levels of Stanniocalcin 2 in patients with colorectal cancer［J］. Med Oncol, 2014, 31(10): 237. DOI: 10.1007/s12032-014-0237-8. ［9］ Wang Y, Gao Y, Cheng H, et al. Stanniocalcin 2 promotes cell proliferation and cisplatin resistance in cervical cancer［J］. Biochem Biophys Res Commun, 2015, 466(3): 362-368. DOI: 10.1016/j.bbrc.2015.09.029. ［10］ Yang S, Ji Q, Chang B, et al. STC2 promotes head and neck squamous cell carcinoma metastasis through modulating the PI3K/AKT/Snail signaling［J］. Oncotarget, 2017, 8(4): 5976-5991. DOI: 10.18632/oncotarget.13355. ［11］ Wu F, Li TY, Su SC, et al. STC2 as a novel mediator for Mus81dependent proliferation and survival in hepatocellular carcinoma［J］. Cancer Lett, 2017, 388: 177-186. DOI: 10.1016/j.canlet.2016.11.039. ［12］马翔, 陈双倩, 王国洲, 等. 斯钙素2蛋白在结直肠癌中表达及其临床意义［J］. 中华实验外科杂志, 2015, 32(7): 1701-1703. DOI: 10.3760/cma.j.issn.1001-9030.2015.07.072. ［13］ Singh M, Yelle N, Venugopal C, et al. EMT: mechanisms and therapeutic implications［J］. Pharmacol Ther, 2018, 182: 80-94. DOI: 10.1016/j.pharmthera.2017.08.009. ［14］ Hou J, Wang Z, Xu H, et al. Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin1mediated signaling［J］. PLoS One, 2015, 10(4): e0122179. DOI: 10.1371/journal.pone.0122179. ［15］ Vaupel P, Mayer A. Tumor hypoxia: causative mechanisms, microregional heterogeneities, and the role of tissuebased hypoxia markers［J］. Adv Exp Med Biol, 2016, 923: 77-86. DOI: 10.1007/978-3-319-38810-6_11. ［16］ Law AY, Wong CK. Stanniocalcin2 is a HIF1 target gene that promotes cell proliferation in hypoxia［J］. Exp Cell Res, 2010, 316(3): 466-476. DOI: 10.1016/j.yexcr.2009.09.018. ［17］ Law AY, Wong CK. Stanniocalcin2 promotes epithelialmesenchymal transition and invasiveness in hypoxic human ovarian cancer cells［J］. Exp Cell Res, 2010, 316(20): 3425-3434. DOI: 10.1016/j.yexcr.2010.06.026. ［18］ Miyazaki S, Kikuchi H, Iino I, et al. AntiVEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts［J］. Int J Cancer, 2014, 135(2): 295307. DOI: 10.1002/ijc.28686. ［19］ Yuan Q, Zhan L, Zhang LL, et al. Stanniocalcin 2 induces oxaliplatin resistance in colorectal cancer cells by upregulating Pglycoprotein［J］. Can J Physiol Pharmacol, 2016, 94(9): 929935. DOI: 10.1139/cjpp20150530. ［20］ Cheng H, Wu Z, Wu C, et al. Overcoming STC2 mediated drug resistance through drug and gene codelivery by PHBPDMAEMA cationic polyester in liver cancer cells［J］. Mater Sci Eng C Mater Biol Appl, 2018, 83: 210-217. DOI: 10.1016/j.msec.2017.08.075. ［21］ Law AY, Wong CK. Stanniocalcin1 and 2 promote angiogenic sprouting in HUVECs via VEGF/VEGFR2 and angiopoietin signaling pathways［J］. Mol Cell Endocrinol, 2013, 374(1-2): 7381. DOI: 10.1016/j.mce.2013.04.024. ［22］ Kim PH, Na SS, Lee B, et al. Stanniocalcin 2 enhances mesenchymal stem cell survival by suppressing oxidative stress［J］. BMB Rep, 2015, 48(12): 702-707. ［23］ Feng L, Ma J, Ji H, et al. MiR184 retarded the proliferation, invasiveness and migration of glioblastoma cells by repressing stanniocalcin2［J］. Pathol Oncol Res, 2018, 24(4): 853-860. DOI: 10.1007/s12253-017-0298-z. ［24］张存良, 关中, 彭解人. 斯钙素2在喉鳞状细胞癌中的表达及预后的相关性研究［J］. 临床耳鼻咽喉头颈外科杂志, 2015, 29(2): 102-107. DOI: 10.1320/j.issn.1001-1781.2015.02.002. ［25］ Lin S, Guo Q, Wen J, et al. Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas［J］. J Exp Clin Cancer Res, 2014, 33(1): 26. DOI: 10.1186/1756-9966-33-26. ［26］ Fang Z, Tian Z, Luo K, et al. Clinical significance of stanniocalcin expression in tissue and serum of gastric cancer patients［J］. Chin J Cancer Res, 2014, 26(5): 602-610. DOI: 10.3978/j.issn.10009604.2014.10.08.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.